心筋梗塞の高齢患者における身体活動介入 (PIpELINe)
心筋梗塞の高齢患者における早期のテーラード身体活動介入の有効性:PIpELINE無作為化臨床試験
Elderly patients presenting with myocardial infarction (MI) are the highest risk population with the worst prognosis. No trial has ever been designed to optimize their outcome through a systematic improvement of their physical performance. Cardiac rehabilitation demonstrated to improve prognosis of patients after MI. However, real-life data shows that older patients are not referred to rehabilitation centers or they have low rate of attendance because of the high number of rehabilitation sessions and of logistic problems. So, data about effectiveness of rehabilitation programs in older MI patients is lacking.
The "Physical Activity Intervention for Elderly Patients with Reduced Physical Performance after acute coronary syndrome (HULK)" pilot study (NCT03021044) enrolled older MI patients and it demonstrated the feasibility and effectiveness of an early, tailored and low-cost physical activity intervention in terms of physical performance assessed by Short Physical Performance Battery (SPPB) score, that is strongly related to prognosis. The HULK study was focused on exercise training and not powered for hard endpoints. If a multi-domain lifestyle intervention in an adequately powered study may further improve prognosis is unknown. Thus, the investigator's hypothesis for the PIpELINe trial is that an early, tailored and low-cost multi-domain lifestyle intervention may improve prognosis of older MI patients compared to health education alone. The primary outcome is a composite of 1-year cardiovascular death and hospital readmission for cardiovascular cause.
調査の概要
詳細な説明
The PIpELINe trial will include older MI patients. All patients aged 65 years and older undergoing coronary angiography because of MI must be screened for eligibility. Patient's eligibility must be assessed after percutaneous revascularization of all lesions considered susceptible of treatment. After verifying inclusion and exclusion criteria and after eligibility is confirmed, written informed consent must be obtained prior to randomization. At the time of the discharge (T0) SPPB test will be performed; in case of a score between 4 and 9, the patient will be evaluated 1-month after discharge at the inclusion visit (T1). If SPPB value is confirmed to be between 4 and 9, randomization will be performed. Key baseline patient characteristics (i.e., inclusion/exclusion criteria, demographics, medical history, details of cardiovascular anatomy and of revascularization, ECG and laboratory test results, echocardiographic data during the index hospitalization) will be recorded on the electronic Case Report Forms (eCRF). All angiographic and echocardiographic data will be collected and forwarded to a core lab for further assessment.
Randomization will be performed during the inclusion visit (T1), 30 days after discharge. Randomization will be performed centrally using an internet-based system. The patient identification number (Patient ID) and the treatment allocation will be assigned by the central randomization system. Patients will be randomized to physical activity group or health education group by a 2:1 allocation. Treatment allocation will be assigned according to a computer-generated randomization list stratified by center. All randomized patients are irrevocably in the study, whether or not they are subsequently found to be eligible, or actually receiving the allocated treatment. Therefore, all patients must be followed until the pre-specified study end date.
The aim of the study is to demonstrate that the proposed multi-domain lifestyle intervention reduces the composite endpoint of cardiovascular death and hospital readmission for cardiovascular cause. The primary endpoint is at 1 year. The follow-up will be extended up to 2 and 3 years.
The protocol includes 3 pre-specified substudies. The possibility to participate in the substudy is left to patient's decision and doesn't preclude the procedures of the main protocol.
- Anxiety and depression: previous studies reported an association between cardiovascular events and a subsequent appearance of mood disorders which could determine a lack in following secondary prevention recommendations. No data is available about these disorders in older adults. In order to assess depression after MI in older patients and the effect of physical activity intervention on mood disorders, this sub-study will be performed.
- Mitochondrial function: in both study groups the mitochondrial functional are investigated starting from blood samples and skin biopsy. Skin biopsy is performed to obtain fibroblasts. In-vitro assessment of the mitochondrial function is done on the fibroblasts of patients. The parameters obtained are related with the effectiveness of physical intervention and with the benefit obtained. A total of at least 30 patients is required.
- Lymphocyte and miRNA activity: taking into account the immunosenescence and the benefits of physical activity on the immune system, this sub-study aims to obtain data regarding T-lymphocyte function in older adults and to assess the effect of physical activity intervention on the function of the different groups of T-lymphocyte. Analyses of physical activity effects on micro ribonucleic acids (miRNAs) are also performed.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Bologna、イタリア
- UO Cardiologia, Ospedale Maggiore
-
Ferrara、イタリア
- Cardiology Unit
-
Lagosanto、イタリア
- Cardiologia Riabilitativa, AUSL d Ferrara
-
Piacenza、イタリア
- Medicina dello Sport, AUSL Piacenza
-
-
BO
-
Bologna、BO、イタリア
- Medicina dello Sport SSD
-
-
FE
-
Ferrara、FE、イタリア
- Centro Studi Biomedici applicati allo Sport, Ferrara
-
-
PC
-
Piacenza、PC、イタリア
- Ospedale Guglielmo da Saliceto, Piacenza
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patients ≥65 years
- Hospital admission for myocardial infarction
- Invasive management during index hospitalization including coronary artery angiography (± percutaneous coronary revascularization)
- SPPB value 4-9 at 1-month visit after hospital discharge
- Informed consent
Exclusion Criteria:
- Multivessel coronary artery disease or left main coronary artery disease candidate to surgical revascularization
- Planned staged percutaneous coronary intervention (PCI)
- Non-cardiovascular co-morbidity reducing life expectancy to < 1 year
- Any factor precluding 1-year follow-up
- Severe aortic or mitral disease
- Ejection fraction <30%
- Chronic heart failure New York Heart Association (NYHA) III-IV
- Severe cognitive impairment (SPMSQ <4)
- Impossibility to do physical activity due to physical impairment
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Health Education
All patients randomized to health education received a single in-person visit, one month post discharge, which included a 30-minute counselling session, supported by educational materials and tailoring of the medical treatment. The educational material provided standardized recommendations on diet, smoking cessation, and physical activity. Quality of life, functional capacity and home physical activity are assessed by proper tools. |
Current gold standard in older patients admitted to hospital for MI. The group will receive a 20-minute session with one of the study physicians. Both the patient and relatives will attend these sessions. The study physician will stress the major issues related to a heart-healthy lifestyle and will explain the importance of PA as a powerful and independent factor to improve cardiovascular health and minimize cardiovascular risk. A detailed brochure explaining the benefits of physical activity will be provided to all patients |
|
実験的:Multi-domain lifestyle intervention
All patients randomized to experimental arm will receive diet counselling, aggressive control of CV risk factors, smoke cessation program and exercise training. The physical activity (PA) intervention will start the program with a supervised PA session immediately after the inclusion visit. Quality of life, functional capacity and daily activities will be assessed by proper tools. The program provides 6 supervised PA sessions (30, 60, 90, 180, 270 and 360 days after hospital discharge [T0]). At the end of each supervised session, calisthenics exercises derived from Otago Exercise Program are prescribed. |
The intervention includes diet counselling, smoke cessation program, aggressive CV risk control and PA intervention. The PA intervention consisted of supervised sessions combined with an individualized home-based PA program. Centre-based sessions will be supervised by a sports physician and a nurse, and will take approximately 30 to 40 minutes, including a moderate standardized treadmill-walk, and strength and balance exercises. Based on the practice sessions, patients will receive a walking program to perform at home, unsupervised. The PA programs will be individualized, and consistent with current international recommendations. A selection of calisthenic exercises will be prescribed. Participants will be encouraged to perform the exercises three times per week (approximately 20 minutes). Adjustment of the type and intensity of the home-based PA regimen will be made at each visit. The PA program will be extensively described to the patient and family members. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cumulative occurrence of cardiovascular death and hospital readmission for cardiovascular cause
時間枠:1-year
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of 1-year composite endpoint of cardiovascular death plus hospital readmission for cardiovascular cause. |
1-year
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cumulative occurrence of all-cause death
時間枠:1-year
|
To test the superiority of the early and tailored physical activity intervention over the health education alone in terms of all-cause death |
1-year
|
|
Cumulative occurrence of all-cause death
時間枠:3-year
|
To test the superiority of the early and tailored physical activity intervention over the health education alone in terms of all-cause death |
3-year
|
|
Cumulative occurrence of cardiovascular death
時間枠:1-year
|
To test the superiority of the early and tailored physical activity intervention over the health education alone in terms of cardiovascular death |
1-year
|
|
Cumulative occurrence of cardiovascular death
時間枠:3-year
|
To test the superiority of the early and tailored physical activity intervention over the health education alone in terms of cardiovascular death |
3-year
|
|
Cumulative occurrence of hospital readmission for cardiovascular cause
時間枠:1-year
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of hospital readmission for cardiovascular cause. |
1-year
|
|
Cumulative occurrence of hospital readmission for cardiovascular cause
時間枠:3-year
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of composite endpoint of hospital readmission for cardiovascular cause. |
3-year
|
|
Cumulative occurrence of cardiovascular death and hospital readmission for cardiovascular cause
時間枠:3-year
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of composite endpoint of cardiovascular death plus hospital readmission for cardiovascular cause. |
3-year
|
|
Cumulative occurrence of hospital readmission for heart failure
時間枠:1-year
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of hospital readmission for heart failure |
1-year
|
|
Cumulative occurrence of hospital readmission for heart failure
時間枠:3-year
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of hospital readmission for heart failure |
3-year
|
|
Cumulative occurrence of hospital readmission for myocardial infarction
時間枠:1-year
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of hospital readmission for myocardial infarction |
1-year
|
|
Cumulative occurrence of hospital readmission for myocardial infarction
時間枠:3-year
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of hospital readmission for myocardial infarction |
3-year
|
|
Cumulative occurrence of hospital readmission for coronary revascularization
時間枠:1-year
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of hospital readmission for coronary revascularization |
1-year
|
|
Cumulative occurrence of hospital readmission for coronary revascularization
時間枠:3-year
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of hospital readmission for coronary revascularization |
3-year
|
|
Cumulative occurrence of cerebrovascular accident
時間枠:1-year
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of cerebrovascular accident |
1-year
|
|
Cumulative occurrence of cerebrovascular accident
時間枠:3-year
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of cerebrovascular accident |
3-year
|
|
Cumulative occurrence of hospital readmission for any cause
時間枠:1-year
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of hospital readmission for any cause |
1-year
|
|
Cumulative occurrence of hospital readmission for any cause
時間枠:3-year
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of hospital readmission for any cause |
3-year
|
|
Cumulative occurrence of hospital readmission for any non-cardiovascular cause
時間枠:1-year
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of hospital readmission for any non-cardiovascular cause |
1-year
|
|
Cumulative occurrence of hospital readmission for any non-cardiovascular cause
時間枠:3-year
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of hospital readmission for any non-cardiovascular cause |
3-year
|
|
Cumulative occurrence of bleeding adverse events
時間枠:1-year
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of bleeding adverse events |
1-year
|
|
Cumulative occurrence of bleeding adverse events
時間枠:3-year
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of bleeding adverse events |
3-year
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Short Physical Performance Battery
時間枠:6-month
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of physical performance (SPPB ranges from 0 to 12, higher values mean better physical performance) |
6-month
|
|
Short Physical Performance Battery
時間枠:1-year
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of physical performance (SPPB ranges from 0 to 12, higher values mean better physical performance) |
1-year
|
|
Short Physical Performance Battery
時間枠:3-year
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of physical performance (SPPB ranges from 0 to 12, higher values mean better physical performance) |
3-year
|
|
Handgrip strength
時間枠:6-month
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of physical performance (handgrip strength, ranges from 0 to infinity, higher values mean better physical performance) |
6-month
|
|
Handgrip strength
時間枠:1-year
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of physical performance (handgrip strength, ranges from 0 to infinity, higher values mean better physical performance) |
1-year
|
|
Handgrip strength
時間枠:3-year
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of physical performance (handgrip strength, ranges from 0 to infinity, higher values mean better physical performance) |
3-year
|
|
Gait speed
時間枠:6-month
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of physical performance (10 meters gait speed ranges from 0 to infinity, higher values mean better physical performance) |
6-month
|
|
Gait speed
時間枠:1-year
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of physical performance (10 meters gait speed ranges from 0 to infinity, higher values mean better physical performance) |
1-year
|
|
Gait speed
時間枠:3-year
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of physical performance (10 meters gait speed ranges from 0 to infinity, higher values mean better physical performance) |
3-year
|
|
EQ5D visual analogue scale
時間枠:6-month
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of quality of life (EQ5D VAS points) |
6-month
|
|
EQ5D visual analogue scale
時間枠:1-year
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of quality of life (EQ5D VAS points) |
1-year
|
|
EQ5D visual analogue scale
時間枠:3-year
|
To assess the superiority of the early and tailored physical activity intervention over health education alone in terms of quality of life (EQ5D VAS points) |
3-year
|
協力者と研究者
出版物と役立つリンク
一般刊行物
- Tonet E, Raisi A, Zagnoni S, Chiaranda G, Pavasini R, Vitali F, Gibiino F, Campana R, Boccadoro A, Scala A, Canovi L, Amantea V, Matese C, Berloni ML, Piva T, Zerbini V, Cardelli LS, Pasanisi G, Mazzoni G, Casella G, Grazzi G, Campo G. Multi-domain lifestyle intervention in older adults after myocardial infarction: rationale and design of the PIpELINe randomized clinical trial. Aging Clin Exp Res. 2023 May;35(5):1107-1115. doi: 10.1007/s40520-023-02389-9. Epub 2023 Mar 25.
- Dal Passo B, Tonet E, Raisi A, Zagnoni S, Chiaranda G, Pasanisi G, Pavasini R, Cimaglia P, Piva T, Casella G, Caglioni S, Zerbini V, Cocco M, Menegatti E, Mandini S, Mazzoni G, Biscaglia S, Volpato S, Grazzi G, Campo G. Effectiveness of Multidomain Cardiac Rehabilitation After Myocardial Infarction by Patient Frailty: Prespecified Subgroup Analysis of the PIpELINe Trial. Circ Popul Health Outcomes. 2026 Aug 17:e013410. doi: 10.1161/CIRCOUTCOMES.126.013410. Online ahead of print.
- Tonet E, Raisi A, Zagnoni S, Chiaranda G, Pasanisi G, Aschieri D, D'Intino PE, Pavasini R, Cimaglia P, Campana R, Vitali F, Piva T, Casella G, Caglioni S, Zerbini V, Bugani G, Cocco M, Menegatti E, De Raffele M, Mandini S, Martella D, Pesenti N, Mazzoni G, Biscaglia S, Volpato S, Grazzi G, Campo G; PIpELINe Trial Investigators. Multidomain Rehabilitation for Older Patients with Myocardial Infarction. N Engl J Med. 2025 Sep 11;393(10):973-982. doi: 10.1056/NEJMoa2502799. Epub 2025 Aug 29.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 376/2019/Sper/AOUFe
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD 共有時間枠
After publication of the main findings
IPD 共有アクセス基準
It will be necessary a formal request to the Executive Committee of the study. The request will be analyzed and considered for acceptance
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- ICF
- ANALYTIC_CODE
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。